Introduction
Cancer is a major life-threatening disease worldwide. Approximately 14.1 million patients were newly diagnosed with cancer and 8.2 million people died from cancer in 2012 worldwide [1] . The global burden of cancer is expected to grow rapidly due to aging population [2] .
In Korea, cancer accounts for one in four deaths and more than 200,000 new cancer cases were diagnosed in 2014 [3] .
The number of cancer incidences and deaths are expected to increase with the aging population and westernized lifestyles [4] . Additionally, the economic burden of cancer in Korea increased approximately 1.8-fold, from $11,424 to $20,858 million, between 2000 and 2010 [5] .
In this context, cancer statistics are the most important indicator of the national cancer burden and can be used to form cancer prevention and control strategies. This study aims to provide nationwide cancer statistics including the incidence, survival, prevalence, and mortality in 2015.
Materials and Methods

Data sources
The Korea Central Cancer Registry (KCCR) was established by the Ministry of Health and Welfare in 1980 as a nationwide hospital-based cancer registry. Since 1999, the KCCR has collected cancer incidence data for the entire nation by compiling a nationwide hospital-based KCCR database that contains data from regional cancer registry programs. The KCCR currently provides the nationwide cancer incidence, survival, and prevalence statistics annually [6] .
The KCCR constructed the Korea National Cancer Incidence Database (KNCI DB) using hospitals data, 11 population-based registries, and additional medical chart reviews. The KNCI DB contains information regarding the age, sex, address, date of diagnosis, primary cancer site, histological type, most valid diagnostic method, and Surveillance, Epidemiology, and End Results (SEER) stage. The completeness of cancer incidence data for 2015 was estimated to be 98.2% based on the method proposed by Ajiki et al. [7] . The midyear population and cancer mortality data from 1983 to 2015 were obtained from Statistics Korea [8] . To ascertain vital status and to calculate survival and prevalence, the KNCI DB was linked to the mortality data and population registration data established by the Ministry of the Interior and Safety.
Classification
All incident cases were registered according to the International Classification of Diseases for Oncology, third edition [9] , and converted to the International Classification of Diseases, 10th edition (ICD-10) codes [10] . The mortality cases were registered according to ICD-10 codes. All cancer cases were reported based on the 24 cancer types.
Statistical analyses
Rates were expressed as crude and age-standardized rates (CR and ASR, respectively) per 100,000 individuals. The CR was calculated as the total number of incidence/mortality cases divided by the mid-year population for the specified years. The ASR is a weighted average of the age-specific rates, where the weights are the proportions of persons in the corresponding age groups of a standard population [11] . In this report, ASRs were calculated using Segi's world standard population [12] . The cumulative risk of developing cancer from birth to life expectancy was calculated using cumulative rates; that is, the sum of the age-specific rates from birth to life expectancy, as follows [13] :
Cumulative risk of developing cancer =100(1-e -cumulative rate ) from birth to life expectancy 100 Trends in incidence/mortality rates were summarized as an annual percentage change (APC) by using a Joinpoint regression. APC is the average percentage change of rates and is calculated as follows [11] :
, where log(Ry)=b0+b1y, log(Ry) is the natural log transformed age standardized rates.
y=year, b0=intercept, b1=slope
The survival duration for each cancer case was calculated as the interval between the date of the initial diagnosis and the date of death, date of loss to follow-up, or closing date for follow-up. The 5-year relative survival rates (RSRs) were calculated as the ratios of the observed survival of the cancer patients to the expected survival of the general population, which was derived from the standard life table provided by Statistics Korea. Trends in 5-year RSRs were evaluated as percentage differences in 5-year RSRs from 1993-1995 and 2011-2015. RSRs were calculated using the Ederer II method [14] with some minor corrections, based on an algorithm established by Paul Dickman [15] .
Prevalent cases were defined as the number of cancer patients alive on January 1, 2016 among all cancer patients diagnosed between 1999 and 2015. Limited-duration prevalences were calculated using SEER*Stat software. Any p-values less than 0.05 were considered statistically significant. SEER*Stat 8.2.1 (National Cancer Institute, Bethesda, MD), Joinpoint 4.1.1 (National Cancer Institute), and SAS 9.4 (SAS Institute Inc., Cary, NC) were used in this report.
Selected Findings
Incidence
A total of 214,701 cases were newly diagnosed with cancer during 2015 (Table 1) . Of these cases, 113,335 (52.8%) were men and 101,366 (47.2%) were women. Stomach cancer was the most commonly diagnosed cancer in 2015, followed by colorectal, thyroid, lung, and breast cancer. The overall cumulative risk of developing cancer from birth to life expectancy was 35.3%. However, the cumulative risk of developing cancer from birth to life expectancy was higher in men (37.9%) than in women (32.0%) (data not shown).
The total CR and ASR for the overall cancer incidences in 2015 were 421.4 and 258.9 per 100,000, respectively ( Table 2) . According to sex, the CRs for all sites combined were 445.2 in men and 397.6 in women. The ASRs were 291.7 and 241.1 in men and women, respectively. Stomach cancer (CR, 76.8) was the most common cancer in men, followed by lung (CR, 66.8), colorectal (CR, 62.5), liver (CR, 46.1), and prostate cancer (CR, 40.1). These five cancers accounted for 65.7% of the newly diagnosed cases in men during the study period. In contrast, thyroid cancer (CR, 77.1) was the most common cancer among women, followed by breast (CR, 75.1), colorectal (CR, 42.7), stomach (CR, 37.9), and lung cancer (CR, 28.4), which five cancers accounted for 65.7% of the cases in women.
Mortality
In 2015, the total number of deaths from cancer was 76,855, accounting for 27.9% of all deaths (Table 3 ). In terms of sex, 62.0% and 38.0% of cancer deaths occurred in men and women, respectively ( Table 1) .
The total CR and ASR for cancer deaths were 150.8 and 82.0 per 100,000, respectively, in 2015 ( Table 4 ). The total CR and ASR for cancer deaths per 100,000 were higher among men (CR, 187.3; ASR, 119.6) than among women (CR, 114.4; ASR, 54.6).
According to cancer sites, lung cancer (CR, 49.8) was the leading cause of death in men, followed by liver (CR, 32.9), stomach (CR, 21.6), colorectal (CR, 18.5), and pancreatic cancer (CR, 11.4). The top five causes of deaths from cancer in Limited-duration prevalent cases on January 1, 2016. These are patients who were diagnosed between January 1, 1999 and December 31, 2015 and who were alive on January 1, 2016. Multiple primary cancer cases were counted multiple times,
Include the gallbladder and other/unspecified parts of the biliary tract. CNS, central nervous system. a) Age-adjusted using the Segi's world standard population, b) Includes the gallbladder and other/unspecified parts of the biliary tract. Age-adjusted using the Segi's world standard population.
women included lung (CR, 18.5), colorectal (CR, 14.1), stomach (CR, 11.8), liver (CR, 11.5), and pancreatic cancer (CR, 9.9).
Trends in cancer incidence and mortality
Fig . 1 shows the trends in cancer incidence and mortality from 1983 to 2015. The ASR for all-cancer incidence increased by 3.4% annually from 1999 to 2012, and then began to decrease from 2012 to 2015 (APC, -6.1%) ( Table 5 , Fig. 1 ). The incidence of cancers in stomach, colorectum, lung and thyroid started to decrease around 2011. Especially, the ASR for thyroid cancer has increased rapidly 22.8% from 1999 to 2011, but then decreased swiftly 13.3% annually starting in 2011. Incidence of breast cancer has increased constantly throughout the period, but the APC slowly started to decrease since 2007. Conversely, the incidence rates of cervix and liver CNS, central nervous system. a) Age-adjusted using the world standard population, b) Includes the gallbladder and other/ unspecified parts of the biliary tract. Includes the gallbladder and other/unspecified parts of the biliary tract. Includes the gallbladder and other/unspecified parts of the biliary tract. ill-defined VOLUME 50 NUMBER 2 APRIL 2018 309
showed a constant decrease for the whole period. The incidence of liver cancer decreased drastically starting in 2010 (Fig. 2) .
The ASR for the all-cancer mortality rate has been increased until 2002 (Table 6 , Fig. 1) . After that year, it began to decrease (2002-2015, APC, -2.7%). Similar patterns were observed in men and women. According to cancer sites, the mortality rates for most cancers including those of the lung, liver, colorectum, gallbladder, leukemia, brain and central nervous system, cervix uteri, and thyroid started to decrease in the early 2000s. However, the mortality rates for cancers of the stomach, larynx, testis, bladder, and non-Hodgkin lymphoma decreased starting in 1999 (Fig. 3) . Cancers in the pancreas, breast, and prostate showed constant increasing 
Age-specific incidence
Leukemia was the most commonly diagnosed cancer among children aged 0-14 years (Table 7) . Thyroid cancer was the most common cancer among adolescents and young adults between 15 and 34 years of age. For men, the incidence rate of cancer increased before age 70 years (Fig. 4A) . Stomach cancer was the most commonly diagnosed cancer among men aged 35 to 64 years, while lung cancer was the most common among men aged  65 years. In contrast, breast cancer was most commonly diagnosed among women aged 35-64 years, while colorectal cancer was the most common among women aged  65 years. The incidence rates for thyroid and breast cancer showed an inverted U-shaped pattern when analyzed according to age (Fig. 4B) . CNS, central nervous system. 
Survival rates
The 5-year RSRs for all cancer combined improved remarkably in both sexes, from 41.2% in 1993-1995 to 70.7% in 2011-2015 (Table 8 , Fig. 5A ). After excluding thyroid cancer, the 5-year RSRs for all cancer still increased from 1993 to 2015 (Fig. 5B) .
The 5-year RSR during 2011-2015 for all cancers combined was 62.8% in men and 78.4% in women, respectively. The 5-year RSR for thyroid cancer was over 100%, while the 5-year RSRs for testis, prostate, and breast cancer were over 90% in 2011-2015 for both sexes. However, the 5-year RSR for pancreatic cancer was only 10.8% in both sexes in [2011] [2012] [2013] [2014] [2015] .
When compared to the 5-year RSR for men in 1993-1995, prostate cancer diagnosed from 2011 to 2015 showed the most outstanding improvement, followed by stomach, leukemia, "lip, oral cavity and pharynx" and liver cancer. Among women, stomach cancer diagnosed during 2011-2015 showed the greatest improvement in 5-year RSRs compared to those between 1993 and 1995, followed by leukemia, lung, colorectal, and kidney cancer.
Prevalence
A total of 1,611,487 prevalent cancer cases were identified on January 1, 2016 (Table 1) . Of these cases, 707,977 (43.9%) were men and 903,510 (56.1%) were women. The crude and age-standardized prevalence rates for overall cancer were 3,162.8 per 100,000 individuals and 1,956.9 per 100,000 indi- Crude prevalence rate: number of prevalent cases divided by the corresponding person-years of observation. Prevalent cases were defined as patients who were diagnosed between January 1, 1999 and December 31, 2015 and who were alive on January 1, 2016. Multiple primary cancer cases were counted multiple times, b)
Age-adjusted using the Segi's world standard population, c)
Includes the gallbladder and other/unspecified parts of the biliary tract. 
